SCHEMBL7561407

SCHEMBL7561407

Cc1c(C(=O)NN=Cc2ccc([N+](=O)[O-])o2)[nH]c2ccccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MITF O75030 5/20 0.57
POLB P06746 4/20 0.57
RAB9A P51151 3/20 0.57
TDP1 Q9NUW8 3/20 0.57
HTT P42858 2/20 0.57
MAPT P10636 7/20 0.56
HSP90AA1 P07900 1/20 0.56
ALDH1A1 P00352 5/20 0.55
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
LMNA P02545 4/20 0.55
NOD2 Q9HC29 3/20 0.55
NOD1 Q9Y239 1/20 0.55
KDM4E B2RXH2 4/20 0.55
NPSR1 Q6W5P4 2/20 0.55
BLM P54132 1/20 0.55
SAE1 Q9UBE0 1/20 0.55
UBA2 Q9UBT2 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
CYP3A4 P08684 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7561404 1.00 MITF (0.57) MITFPOLBRAB9ATDP1HTT
SCHEMBL7558170 0.87 TDP1 (0.54) MITFPOLBRAB9ATDP1HTT
SCHEMBL7558176 0.87 TDP1 (0.54) MITFPOLBRAB9ATDP1HTT
SCHEMBL7563854 0.86 MEN1 (0.57) MITFPOLBRAB9ATDP1HTT
SCHEMBL7563859 0.86 MEN1 (0.57) MITFPOLBRAB9ATDP1HTT
SCHEMBL7559734 0.85 MAPT (0.65) RAB9AHTTMAPTALDH1A1MEN1
SCHEMBL7559736 0.85 MAPT (0.65) RAB9AHTTMAPTALDH1A1MEN1
SCHEMBL7557760 0.79 MAPT (0.74) MITFPOLBRAB9AHTTMAPT
SCHEMBL7557764 0.79 MAPT (0.74) MITFPOLBRAB9AHTTMAPT
SCHEMBL7559838 0.78 MAPK1 (0.64) POLBRAB9ATDP1MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US claimed
WO-2002022576-A2 3-SUBSTITUTED INDOLE CARBOHYDRAZIDES USEFUL AS CELL PROLIFERATION AND ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2002-03-21 WO claimed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US claimed
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors ABBOTT LABORATORIES 2002-07-11 US disclosed
US-6323228-B1 INHIBITING ANGIOGENESIS IN A MAMMAL IN RECOGNIZED NEED OF SUCH TREATMENT COMPRISING ADMINISTERING TO THE MAMMAL WITH INDOLE SUBSTITUTED WITH HYDRAZIDES ABBOTT LABORATORIES 2001-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091148-A1 3-substituted indole antiproliferative angiogenesis inhibitors MKI67, FLT4, IDO1 MITF 934/4885POLB 2880/4885RAB9A 3961/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.